Grants and Contributions:
Title:
Development of Novel CB1 Blockers
Agreement Number:
978964
Agreement Value:
$249,500.00
Agreement Date:
Sep 13, 2021 - Jun 3, 2022
Description:
The ultimate goal of the project is to develop new generation CB1 receptor blockers for clinical advancement applying key learnings from its CB1 receptor antagonist program.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H3B 4N4
Reference Number:
172-2021-2022-Q2-978964
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
821124369
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 82 days. The total amended value is 150,000 dollars.
Amendment Date
Mar 21, 2022
Recipient's Legal Name:
Inversago Pharma Inc
Federal Riding Name:
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number:
24077
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: